Photocure ASA: Results for the third quarter of 2021
Oslo, Norway, 17 November 2021: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 86.7 million in the third quarter of 2021 (Q3 2020: NOK 49.6), and EBITDA of NOK -0.2 million (-5.4), following the continued successful launch in markets previously operated by Ipsen Pharma SAS. The Company plans to increase its investment in commercial activities to further penetrate the large potential market opportunity for its bladder cancer treatment.“Photocure continued to grow its business during the third quarter of 2021, despite the challenges that arose from the surge of